EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and...
China Matters' Feature: Green and Low-Carbon Development - A Path Toward Sustainability
BEIJING, Nov. 20, 2024 /PRNewswire/ -- In the face of dual global crises—climate change and nature loss—green and low-carbon development has emerged as an urgent priority. According to Zhao Liang, Project Coordinator of Policy Advocacy and Greening...